Fax: (617) 632-2616
Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy†‡
Results from Cancer and Leukemia Group B 9066
Article first published online: 23 AUG 2005
Copyright © 2005 American Cancer Society
Volume 104, Issue 8, pages 1580–1589, 15 October 2005
How to Cite
Peppercorn, J., Herndon, J., Kornblith, A. B., Peters, W., Ahles, T., Vredenburgh, J., Schwartz, G., Shpall, E., Hurd, D. D., Holland, J., Winer, E. and The Cancer and Leukemia Group B (CALGB) and The Southwestern Oncology Group (SWOG)Group (2005), Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy. Cancer, 104: 1580–1589. doi: 10.1002/cncr.21363
Presented as Abstract 1593 at the annual meeting of the American Society of Clinical Oncology, Atlanta, Georgia, May 15–19, 1999.
The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute.
- Issue published online: 3 OCT 2005
- Article first published online: 23 AUG 2005
- Manuscript Accepted: 19 MAY 2005
- Manuscript Revised: 6 MAY 2005
- Manuscript Received: 16 MAR 2005
- National Cancer Institute. Grant Numbers: CA31946, CA32291, CA33601, CA14028, CA42777, CA03927, CA77651
- assessment scales;
- autologous stem cell support;
- breast carcinoma;
- high-dose chemotherapy;
- quality of life
The objective of this study was to compare the quality of life (QOL) after treatment among patients who had breast carcinoma with multiple positive lymph nodes. The patients were randomized to receive either high-dose chemotherapy with autologous stem cell support (HDC) or intermediate-dose chemotherapy (IDC) in the adjuvant setting.
Two hundred forty-six patients with AJCC Stage IIA, IIB, or IIIA breast carcinoma who had ≥ 10 positive lymph nodes and who were participants in Cancer and Leukemia Group B (CALGB) 9082 were enrolled in this companion study, CALGB 9066. Patients were randomized to receive either high-dose cyclophosphamide, carmustine, and cisplatin (CPA/cDDP/BCNU) and autologous bone marrow transplantation (the HDC arm) or intermediate-dose CPA/cDDP/BCNU as consolidation to adjuvant chemotherapy (the IDC arm). QOL was assessed at baseline and at 3 months, 12 months, 24 months, and 36 months using the Functional Living Index-Cancer (FLIC), the Psychosocial Adjustment to Illness Scale (PAIS)-Self Report, and the McCorkle Symptom Distress Scale (SDS).
At the 3-month assessment, patients in the HDC arm demonstrated significant worsening of QOL compared with the IDC arm in terms of their physical well being (FLIC, P = 0.023), social functioning (FLIC, P = 0.026; PAIS, P < 0.0001), symptom distress (SDS, P = 0.0002), and total QOL scores (FLIC, P = 0.042). At 12 months, the differences in QOL scores between the HDC arm and the IDC arm had resolved.
Patients who received more intensive adjuvant therapy experienced transient declines in QOL. By 12 months after therapy, QOL was comparable between the 2 arms, regardless of therapy intensity, and many QOL areas were improved from baseline. Cancer 2005. © 2005 American Cancer Society.